Aurimune
Phase 2- Indications
- Pancreatic cancer, Melanoma, Soft tissue sarcoma, Ovarian cancer, Breast cancer, Non-small-cell lung cancer
Company intelligence / Profile preview
CytImmune Sciences
Rockville, Maryland, USAcytimmune.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Phase 2
01
Overview
CYT-6091, the company's lead therapeutic, has completed Phase 1 clinical trials at the National Cancer Institute with promising results and is advancing to Phase 2 studies. The Phase 1 trial demonstrated that gold nanoparticles trafficked to tumors, not healthy tissue, improving the safety of systemically administered TNF formulated as CYT-6091[4][5].
- Therapeutic areas
- Oncology
- Modalities
- NanomedicineGold nanoparticlesTNF alpha delivery system
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
AstraZenecaNational Cancer Institute
Beyond the preview
Go deeper on CytImmune Sciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CytImmune Sciences.